Clay Siegall Net Worth

The estimated Net Worth of Clay B Siegall is at least $172 Milion dollars as of 20 May 2024. Clay Siegall owns over 100,000 units of Seagen Inc stock worth over $96,037,895 and over the last 21 years he sold SGEN stock worth over $61,764,245. In addition, he makes $14,521,500 as Chairman of the Board, President oraz Chief Executive Officer at Seagen Inc.

Clay Siegall SGEN stock SEC Form 4 insiders trading

Clay has made over 160 trades of the Seagen Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of SGEN stock worth $1,388,000 on 20 May 2024.

The largest trade he's ever made was exercising 200,000 units of Seagen Inc stock on 14 January 2011 worth over $1,686,000. On average, Clay trades about 16,527 units every 22 days since 2003. As of 20 May 2024 he still owns at least 419,636 units of Seagen Inc stock.

You can see the complete history of Clay Siegall stock trades at the bottom of the page.

Clay Siegall biography

Dr. Clay B. Siegall, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Seattle Genetics, Inc. He co-founded Seattle Genetics in 1997. He has served as our Chief Executive Officer since November 2002, as our President since June 2000, as one of our directors since December 1997 and as our Board chairman since March 2004. Dr. Siegall also served as our Chief Scientific Officer from December 1997 until November 2002. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, most recently as a Principal Scientist. From 1988 to 1991, Dr. Siegall was a Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. In addition to Seattle Genetics, Dr. Siegall serves as a director of Ultragenyx Pharmaceutical Inc. and Alder BioPharmaceuticals, Inc., both publicly-traded biotechnology companies. He served as a director of Mirna Therapeutics, Inc., also a publicly-traded biotechnology company from 2013 to 2016. Dr. Siegall’s experience in founding and building Seattle Genetics is integral to our success and our mission. His scientific understanding along with his corporate vision and operational knowledge provide strategic guidance to our management team and the Board of Directors.

What is the salary of Clay Siegall?

As the Chairman of the Board, President oraz Chief Executive Officer of Seagen Inc, the total compensation of Clay Siegall at Seagen Inc is $14,521,500. There are no executives at Seagen Inc getting paid more.

How old is Clay Siegall?

Clay Siegall is 59, he's been the Chairman of the Board, President oraz Chief Executive Officer of Seagen Inc since 2004. There are 9 older and 8 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.

What's Clay Siegall's mailing address?

Clay's mailing address filed with the SEC is C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011.

Insiders trading at Seagen Inc

Over the last 21 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... oraz Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.

What does Seagen Inc do?

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Complete history of Clay Siegall stock trades at Seagen Inc, Ultragenyx Pharmaceutical, Nurix Therapeutics, Shattuck Labs oraz Immunome

Seagen Inc executives and stock owners

Seagen Inc executives and other stock owners filed with the SEC include:

• Clay Siegall,
  Chairman of the Board, President, Chief Executive Officer
• Roger Dansey,
  Chief Medical Officer
• Todd Simpson,
  Chief Financial Officer
• Jean Liu,
  Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Vaughn Himes,
  Chief Technical Officer
• Dr. Clay B. Siegall,
  Co-Founder, Chairman, Pres & CEO
• Dr. Roger D. Dansey M.D.,
  Chief Medical Officer & Interim CEO
• Jean I. Liu,
  Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.
• Jean I. Liu J.D., M.S.,
  Chief Legal Officer
• Charles R. Romp,
  Exec. VP of Commercial U.S.
• Todd E. Simpson,
  Chief Financial Officer
• Felix Baker,
  Lead Independent Director
• David Gryska,
  Independent Director
• John Orwin,
  Independent Director
• Nancy Simonian,
  Independent Director
• Alpna Seth,
  Independent Director
• Daniel Welch,
  Independent Director
• Marc Lippman,
  Independent Director
• Ted Love,
  Director
• David Caouette,
  VP of Corp. Communications
• Dr. Vaughn B. Himes,
  Chief Technical Officer
• Christopher P. Pawlowicz,
  Exec. VP of HR
• Matt Skelton,
  VP of Marketing
• Natasha A. Hernday,
  Exec. VP of Corp. Devel. & Alliance Management
• Nancy Whiting B.Sc., Pharm.D.,
  Exec. VP of Corp. Strategy, Alliances & Communications
• Peggy Pinkston,
  VP of Investor Relations
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Felixbaker Julian Baker Bro...,
  
• Srinivas Akkaraju,
  Director
• Eric Dobmeier,
  Vice President,
• Bros. Advisors Lp667, L.P.B...,
  
• Sandra M Swain,
  
• Morgan Partners Bhca Lpjpmp...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Robin G Taylor,
  Chief Commercial Officer
• Felix667, L.P.Baker Julian ...,
  
• John Peter Mclaughlin,
  Director
• Felix Baker,
  Director
• Morris Rosenberg,
  SVP, Development
• Bruce J. Seeley,
  EVP, Commerical
• Felix667, L.P.Baker Brother...,
  
• Thomas C Reynolds,
  Chief Medical Officer
• Christopher S. Boerner,
  SVP, Commercial
• Brothers Life Sciences Capi...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Holdings, Inc.H&Q Employee ...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Darren S Cline,
  SVP, Commercial
• Morgan Partners Bhca Lpjpmp...,
  
• Felixbaker Julian Baker Bro...,
  
• Franklin M Berger,
  Director
• Morgan Partners Bhca Lp Jp,
  10% owner
• Daniel Floyd Jr Hoth,
  Director
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Jonathan Gallen,
  10% owner
• Management Partners Vi Llcd...,
  
• Pamela A Trail Smith,
  Chief Scientific Officer
• Brothers Life Sciences Capi...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Biotech Capital Ii (Z) (Gp)...,
  
• Amy Sing,
  Sr. Director Medical Affairs
• Michael Powell,
  Director
• Biotech Capital Iii (Z) (Gp...,
  
• Tim Carroll,
  CFO
• Investment Llc Cascade,
  
• Douglas Southern,
  Director
• Karl Erik Hellstrom,
  Director
• Michael Mcdonald,
  Chief Medical Officer
• Morgan Partners Bhca Lpjpmp...,
  
• Peter Senter,
  Vice President, Chemistry
• H Perry Fell,
  Chairman
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• David R Epstein,
  CEO
• Charles R Romp,
  EVP, Commercial U.S.